

abbvie

AbbVie Pipeline Update

February 9, 2023

AbbVie R&D Pipeline

Phase 1

- CUG-252* (IL-2 Mutein) SLE
- CLF065* (GLP-2 agonist) IBD
- ABBV-151 (GARP+TGFβ1) Solid Tumors
- ABBV-400 (cMet ADC) NSCLC
- ABBV-647* (PTK7 ADC) NSCLC
- ABBV-637 (EGFR BCL-xL ADC) NSCLC
- ABBV-706 (SEZ6 ADC) SCLC
- ABBV-181 (PD-1) Solid Tumors
- ABBV-927 (CD40) Solid Tumors
- JAB-3312* (SHP2) Solid Tumors
- TTX-030* (CD39) Solid Tumors
- ABBV-CLS-579* (PTPN2) Solid Tumors
- ABBV-CLS-484* (PTPN2) Solid Tumors
- ABBV-514 (CCR8) Solid Tumors
- Eftoza (TRAIL) Heme Tumors
- ABBV-319 (CD19/Steroid ADC) Heme Tumors
- ABBV-525 (MALT1) Heme Tumors
- CLBR001/SWI019* (sCAR-T) Heme Tumors
- ABBV-383 (CD3-BCMA) MM
- HPN-217* (CD3-BCMA) MM
- ABBV-453 (BCL-2) R/R MM t(11;14)
- Epcoritamab* (CD3-CD20) R/R CLL and Richter's Syndrome
- ABBV-744 (BET) MF
- ABBV-552 (SV2A) Alzheimer's Disease
- ABBV-CLS-7262* (eIF2B) Multiple Neuro
- AGN-241622 (Alpha2) Presbyopia
- ABBV-1882 (anti-PD1/anti-a4b7) HIV
- ABBV-903 (MPro Inhibitor) COVID

Phase 2

- ABBV-154 (TNF-Steroid ADC) PMR
- ABBV-154 (TNF-Steroid ADC) CD
- Rinvoq (JAK 1) Vitiligo
- Rinvoq (JAK 1) SLE
- Rinvoq (JAK 1) HS
- Acacizolcept ALPN-101* (ICOS/CD28) SLE
- Lutikizumab (IL-1α/1β) HS
- ABBV-668 (RIPK1) UC
- ABBV-CX-2029* (CD71) Solid/Heme Tumors
- Epcoritamab* (CD3-CD20) B-Cell NHL
- ABBV-916 (a-beta) Alzheimer's Disease
- Botox (SNARE) Essential Tremor
- Elezanumab (RGMa) Stroke
- Elezanumab (RGMa) SCI
- AL002* (TREM2) AD
- OnabotA X (SNARE) Glabellar Lines
- OnabotA X (SNARE) Forehead Lines
- AGN-242428 (RORγ) Dry Eye
- ABBV-RGX-314* (NAV AAV8 Anti-VEGF Fab) wAMD Suprachoroidal Delivery
- ABBV-RGX-314* (NAV AAV8 Anti-VEGF Fab) DR Suprachoroidal Delivery
- AGN-193408 (Prostamide 408 SR) Glaucoma
- CF Triple Combo (CFTR-C1/CFTR-C2/CFTR-P)
- Armour Thyroid (T3T4) Hypothyroidism
- AGN-151607 (SNARE) Atrial Fibrillation
- Botox (SNARE) IC/BPS

Registrational / Phase 3

- Rinvoq (JAK 1) GCA
- Skyrizi* (IL-23) UC
- Imbruvica* (BTK) 1L FL
- Imbruvica* (BTK) R/R MCL
- Imbruvica* (BTK) + Venclexta* (BCL-2) R/R MCL
- Venclexta* (BCL-2) AML Maintenance
- Venclexta* (BCL-2) R/R MM t(11;14)
- Venclexta* (BCL-2): High Risk MDS
- Navitoclax (BCL-2/BCL-xL) Myelofibrosis
- Epcoritamab* (CD3-CD20) 1L DLBCL
- Epcoritamab* (CD3-CD20) R/R DLBCL
- Epcoritamab* (CD3-CD20) R/R FL
- Teliso-V* (cMet ADC) NSCLC
- Botox (SNARE) Episodic Migraine
- BoNT/E (SNARE) Glabellar Lines
- Botox (SNARE) Masseter Prominence
- Botox (SNARE) Platysma Prominence
- ABBV-RGX-314* (NAV AAV8 Anti-VEGF Fab) wAMD Subretinal Delivery
- Aztreonam/Avibactam* (PBP3) Infection

Submitted

- Rinvoq (JAK 1) CD
- Epcoritamab* (CD3-CD20): R/R DLBCL
- ABBV-951 (dopamine receptor) Advanced PD
- Qulipta (CGRP) Chronic Migraine Prevention

As of February 9, 2023
Excludes devices in development
*Partnered assets

- Immunology
- Oncology
- Neuroscience
- Aesthetics
- Eye Care
- Targeted Investment

AbbVie - Anticipated Key Pipeline Events

	2023	2024
Regulatory Approvals	<p>Rinvoq CD Epcoritamab R/R DLBCL (AA) ABBV-951 Advanced PD Qulipta Chronic Migraine Prevention</p>	<p>Skyrizi UC Venclexta 3L+ MM w/ t(11;14) Venclexta High Risk MDS Navitoclax 1L MF</p> <p>Teliso V 2L+ NSCLC (AA) Botox Platysma Botox Masseter</p>
Regulatory Submissions	<p>Skyrizi UC Venclexta 3L+ MM w/ t(11;14) Navitoclax 1L MF Botox Platysma Botox Masseter</p>	<p>Rinvoq GCA Teliso-V NSCLC Venclexta High Risk MDS Navitoclax r/r MF Botox Episodic Migraine BoNT/E (Short-Acting Toxin) Glabellar Lines</p>
Ph3/Registrational Data Readouts	<p>Skyrizi UC Induction/Maintenance Venclexta Ph3 3L+ MM t(11;14) (CANOVA) Navitoclax Ph3 1L MF (Transform-1) Epcoritamab Ph3 3L DLBCL Teliso-V Ph2 2L+ NSCLC Botox Ph3 Masseter Botox Ph3 Platysma BoNT/E (Short-Acting Toxin) Ph3 Glabellar Lines</p>	<p>Rinvoq Ph3 GCA Venclexta Ph3 High Risk MDS Navitoclax Ph3 r/r MF (Transform-2) Botox Ph3 Episodic Migraine ABBV-RGX-314 Ph3 wAMD SR</p>
Early-Stage POC Data Readouts	<p>Rinvoq Vitiligo ABBV-154 (TNF-Steroid ADC) Ph2 PMR TTX-030 (CD39) Ph1 Solid Tumors CLBR001/SWI019 (CD19 sCAR-T) Ph1 Heme Tumors Eftoza (TRAIL) Ph1 Heme Tumors ABBV-637 (EGFR BCL-xLi ADC) Ph1 NSCLC AGN-241622 (Alpha2) Presbyopia</p>	<p>ABBV-154 (TNF-Steroid ADC) Ph2 CD Induction Lutikizumab (IL-1α/1β) Ph2 HS ABBV-CLS-579 (PTPN2) Ph1 Solid Tumors ABBV-CLS-484 (PTPN2) Ph1 Solid Tumors ABBV-400 (c-Met ADC) Ph1 Solid Tumors ABBV-453 (BCL-2) Ph1 MM t(11;14) ABBV-744 (BET) Ph1 MF Elezanumab (RGMa) Ph2 Stroke ABBV-552 (SV2A) Ph2 AD Cognition ABBV-CLS-7262 Ph2 ALS</p>

As of February 9, 2023
AA = Accelerated Approval

AbbVie's Partnered Assets

- ABBV-2029 developed by CytomX Therapeutics through clinical proof of concept and AbbVie holds option for additional development
- ABBV-647 developed in cooperation with Pfizer
- ABBV-CLS-579/484/7262 co-developed by Calico and AbbVie
- Acazicolcept (ALPN-101) developed by Alpine Immune Sciences through current Phase 2 study and AbbVie holds option for additional development
- AL002 developed by Alector through Phase 2 and AbbVie holds option for additional development
- Aztreonam/Avibactam co-developed by Pfizer and AbbVie
- CLBR001/SWI019 developed by Calibr in a first-in-patient trial and AbbVie holds option for additional development
- CLF065 developed by Scripps/Calibr in a first-in-patient trial and AbbVie holds option for additional development
- CUG-252 developed by Cugene through Phase 1b and AbbVie holds option for additional development
- Epcoritamab developed in partnership with Genmab
- HPN-217 developed by Harpoon through Phase 1/2 and AbbVie holds option for additional development
- Imbruvica jointly developed with Janssen Biotech
- JAB-3312 developed in partnership with Jacobio
- RGX-314 co-developed by REGENXBIO and AbbVie
- Skyrizi developed in cooperation with Boehringer Ingelheim
- Teliso-V licensed from Seagen and Pierre Fabre
- TTX-030 developed by Trishula Therapeutics through Phase 1b and AbbVie has option to lead global development
- Venclexta jointly developed with Roche
- Vraylar developed in cooperation with Gedeon Richter